Cited by 896Fatty Acid Research and HealthSchizophrenia research and treatmentBipolar Disorder and Treatment

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Long-Chain ω-3 Fatty Acids for Indicated Prevention of Psychotic Disorders: A Randomized, Placebo-Controlled Trial

Open access

Amminger, G. Paul, Schäfer, Miriam R., Papageorgiou, Konstantinos, Klier, Claudia M., Cotton, Sue M., Harrigan, Susan M., Mackinnon, Andrew, McGorry, Patrick D., Berger, Gregor E.·2010·Archives of General Psychiatry

DOI 10.1001/archgenpsychiatry.2009.192

Open this paper in CoChat — free account Open PDF

Abstract

CONTEXT: The use of antipsychotic medication for the prevention of psychotic disorders is controversial. Long-chain omega-3 (omega-3) polyunsaturated fatty acids (PUFAs) may be beneficial in a range of psychiatric conditions, including schizophrenia. Given that omega-3 PUFAs are generally beneficial to health and without clinically relevant adverse effects, their preventive use in psychosis merits investigation. OBJECTIVE: To determine whether omega-3 PUFAs reduce the rate of progression to first-episode psychotic disorder in adolescents and young adults aged 13 to 25 years with subthreshold psychosis. DESIGN: Randomized, double-blind, placebo-controlled trial conducted between 2004 and 2007. SETTING: Psychosis detection unit of a large public hospital in Vienna, Austria. PARTICIPANTS: Eighty-one individuals at ultra-high risk of psychotic disorder. INTERVENTIONS: A 12-week intervention period of 1.2-g/d omega-3 PUFA or placebo was followed by a 40-week monitoring period; the total study period was 12 months. MAIN OUTCOME MEASURES: The primary outcome measure was transition to psychotic disorder. Secondary outcomes included symptomatic and functional changes. The ratio of omega-6 to omega-3 fatty acids in erythrocytes was used to index pretreatment vs posttreatment fatty acid composition. RESULTS: Seventy-six of 81 participants (93.8%) completed the intervention. By study's end (12 months), 2 of 41 individuals (4.9%) in the omega-3 group and 11 of 40 (27.5%) in the placebo group had transitioned to psychotic disorder (P = .007). The difference between the groups in the cumulative risk of progression to full-threshold psychosis was 22.6% (95% confidence interval, 4.8-40.4). omega-3 Polyunsaturated fatty acids also significantly reduced positive symptoms (P = .01), negative symptoms (P = .02), and general symptoms (P = .01) and improved functioning (P = .002) compared with placebo. The incidence of adverse effects did not differ between the treatment groups. CONCLUSIONS: Long-chain omega-3 PUFAs reduce the risk of progression to psychotic disorder and may offer a safe and efficacious strategy for indicated prevention in young people with subthreshold psychotic states. Trial Registration clinicaltrials.gov Identifier: NCT00396643.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/archgenpsychiatry.2009.192

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2022) · doi:10.1176/appi.books.9780890425787 · Cited by 23,476
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
A systematic review and meta-analysis of the psychosis continuum: evidence for a psychosis proneness-persistence-impairment model of psychotic disorder
van Os, J., Linscott, R. J., Myin-Germeys, I., Delespaul, P., & Krabbendam, L. (2009) · Psychological Medicine · doi:10.1017/s0033291708003814 · Cited by 2,343
Fish Intake, Contaminants, and Human Health: Evaluating the Risks and the Benefits
Mozaffarian, D., & Rimm, E. B. (2006) · JAMA · doi:10.1001/jama.296.15.1885 · Cited by 1,966
The Family History Method Using Diagnostic Criteria
Andreasen, N. C. (1977) · Archives of General Psychiatry · doi:10.1001/archpsyc.1977.01770220111013 · Cited by 1,903
The number needed to treat: a clinically useful measure of treatment effect
Cook, R. J., & Sackett, D. L. (1995) · BMJ · doi:10.1136/bmj.310.6977.452 · Cited by 1,885
The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patients
Lingjærde, O., Ahlfors, U. G., Bech, P., Dencker, S. J., & Elgen, K. (1987) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1987.tb10566.x · Cited by 1,705
Association Between Duration of Untreated Psychosis and Outcome in Cohorts of First-Episode Patients
Marshall, M., Lewis, S. W., Lockwood, A., Drake, R., Jones, P. B., & Croudace, T. J. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.9.975 · Cited by 1,595

Show all 45 references

Research works printed but not linked: 1

First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. New York, NY: Biometrics Research, New York State Psychiatric Institute; 2002.

Sorted by citations

Items 601–700 of 895

Increased brain docosahexaenoic acid has no effect on the resolution of neuroinflammation following intracerebroventricular lipopolysaccharide injection
Trépanier, M., Hopperton, K. E., Giuliano, V., Masoodi, M., & Bazinet, R. P. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2018.05.010 · Cited by 6
DHA (Docosahexaenoic Acid): A Biomolecule with Diverse Roles and Health Benefits
Hei, A., & Sanahanbi, L. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.109677 · Cited by 7
Positive and negative schizotypy personality traits are lower in individuals on ketogenic diet in a non-clinical sample
Garner, S., Barkus, E., & Kraeuter, A.-K. (2024) · Schizophrenia Research · doi:10.1016/j.schres.2024.07.010 · Cited by 6
Early intervention in psychosis in low- and middle-income countries: Applying the same principles as the developed countries
Nasrallah, H. A. (2024) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2024.104131 · Cited by 6
Early Interventions in High Risk Groups for Psychotic Disorders
Erzın, G., & Gülöksüz, S. (2021) · Nöro Psikiyatri Arşivi · doi:10.29399/npa.27404 · Cited by 6
The early identification of psychosis: can lessons be learnt from cardiac stress testing?
Gupta, S., Ranganathan, M., & D’Souza, D. C. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4143-3 · Cited by 6
Schizophrenia Pharmacology: Past, Present, and Future Targets for Intervention
Cronenwett, W. J. (2016) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20160009 · Cited by 7
Real-World Effectiveness and Safety of Antipsychotics in Individuals at Clinical High-Risk for Psychosis: Study Protocol for a Prospective Observational Study (ShangHai at Risk for Psychosis-Phase 2)
Wu, G., Gan, R., Li, Z., Xu, L., Tang, X., Wei, Y., Hu, Y., Cui, H., Li, H., Tang, Y., et al. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s230904 · Cited by 6
Increased PLA2 activity in individuals at ultra-high risk for psychosis
Talib, L. L., Costa, A. C., Joaquim, H. P. G., Pereira, C. A. C., van de Bilt, M. T., Loch, A. A., & Gattaz, W. F. (2021) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-021-01246-y · Cited by 6
A Case of Attenuated Psychosis Syndrome: A Broad Differential Diagnosis Requires Broad-Spectrum Treatment
Cadenhead, K. S., & Mirzakhanian, H. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15060789 · Cited by 6
An Ecological Systems Perspective on the Clinical High Risk State Preceding Schizophrenia Onset
DeVylder, J. (2012) · Social Work in Mental Health · doi:10.1080/15332985.2012.708018 · Cited by 6
Research in young people at ultra-high risk for psychosis: a review of the current evidence
O’Connor, K. (2013) · Irish Journal of Psychological Medicine · doi:10.1017/ipm.2012.9 · Cited by 6
Pharmacological Treatment of Schizophrenia:
Fleischhacker, W. W., & Miyamoto, S. (2016) · Clinical Neuropsychopharmacology and Therapeutics · doi:10.5234/cnpt.7.1 · Cited by 6
Early Intervention for Better Mental Health Services
Rosen, A., Byrne, P., Goldstone, S. D., & McGorry, P. D. (2015) · Wiley eBooks · doi:10.1002/9781118753378.ch99 · Cited by 6
Self-citation
The N-3 polyunsaturated fatty acids supplementation to prevent depression recurrence in patients with late-life depression: a 52-week double-blind, placebo-controlled trial
Cheng, Y.-C., Chen, W.-Y., Lin, C., Lee, S.-H., Chiu, C.-C., & Kuo, P.-H. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.09.129 · Cited by 5
Phospholipids and Insulin Resistance in Psychosis: A Lipidomics Study of Twin Pairs Discordant for Schizophrenia
Orešič, M., Seppänen-Laakso, T., Sun, D., Tang, J., Therman, S., Viehman, R., Mustonen, U., van Erp, T. G., Hyötyläinen, T., Thompson, P., et al. (2012) · Genome Medicine · doi:10.1186/gm300 · Cited by 5
From hallucinations to delusions: A narrative review of psychotic-like experiences and their implications
Logoń, K., Świrkosz, G., & Kowalski, K. (2024) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/186815 · Cited by 7
Prediction and Early Detection of First-Episode Psychosis
Schultze‐Lutter, F., Michel, C., Ruhrmann, S., Klosterkötter, J., & SCHIMMELMANN, B. G. (2011) · Springer eBooks · doi:10.1007/978-94-007-0831-0_9 · Cited by 5
Omega-3 Supplementation Reduces Schizotypal Personality in Children: A Randomized Controlled Trial
Raine, A., Gur, R. C., Gur, R. E., Richmond, T. S., Hibbeln, J. R., & Liu, J. (2024) · Schizophrenia Bulletin · doi:10.1093/schbul/sbae009 · Cited by 5
Omega-3 and omega-6 polyunsaturated fatty acid intake and aberrant behaviors in Jordanian children with autism spectrum disorders (ASD): A pilot study
Rababah, T., Flieh, S. M., Alu'datt, M. H., Gammoh, S., Magableh, G. M., Ajouly, T., Almajwal, A. M., & Al-Rayyan, N. (2024) · Research in Autism · doi:10.1016/j.rasd.2024.102386 · Cited by 6
The rich detail of cultural symbol systems
Read, D. (2014) · Behavioral and Brain Sciences · doi:10.1017/s0140525x13003257 · Cited by 5
Supplementing long‐chain n‐3 polyunsaturated fatty acids in canned wild P acific pink salmon with A laska salmon oil
Lapis, T. J., de Oliveira, A. C. M., Crapo, C. A., HIMELBLOOM, B. H., Bechtel, P. J., & Long, K. A. (2012) · Food Science & Nutrition · doi:10.1002/fsn3.4 · Cited by 5
The effect of omega-3 long chain polyunsaturated fatty acids on aggressive behaviour in adult male prisoners: a structured study protocol for a multi-centre, double-blind, randomised placebo-controlled trial and translation into policy and practice
Meyer, B. J., Byrne, M. K., Cortie, C. H., Parletta, N., Jones, A. L., Eckermann, S. D., Butler, T. G., Greenberg, D. M., Batterham, M. J., Fernandez, F., et al. (2021) · Trials · doi:10.1186/s13063-021-05252-2 · Cited by 6
Nutrition, Exercise, and Stress Management for Treatment and Prevention of Psychiatric Disorders. A Narrative Review Psychoneuroendocrineimmunology-Based
Bottaccioli, F., Bottaccioli, A., Marzola, E., Longo, P., Minelli, A., & Abbate-Daga, G. (2021) · Endocrines · doi:10.3390/endocrines2030022 · Cited by 6
Role of de novo lipogenesis in insulin resistance in first-episode psychosis and therapeutic options
Khan, M. M. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104919 · Cited by 5
Mood Disorders in Youth
Saxena, K., Kurian, S. R., Kumar, R. R., Arnold, L. E., & Simkin, D. R. (2023) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2022.08.012 · Cited by 6
Excessive ingestion of long-chain polyunsaturated fatty acids during developmental stage causes strain- and sex-dependent eye abnormalities in mice
Maekawa, M., Iwayama, Y., Watanabe, A., Nozaki, Y., Ohnishi, T., Ohba, H., Toyoshima, M., Hamazaki, K., Osumi, N., Aruga, J., et al. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.10.051 · Cited by 5
Providing care to young people with emerging risk of psychosis: balancing potential risks and benefits
McGorry, P. D., Nelson, B., & Goldstone, S. D. (2012) · Clinical Practice · doi:10.2217/cpr.12.69 · Cited by 5
Self-citation
Assessment and treatment of the risk of psychosis in adolescents--a review.
Zdanowicz, N., Mees, L., Jacques, D., Tordeurs, D., & Reynaert, C. (2014) · PubMed · Cited by 5
Metabolomics of Psychotic Disorders
Bousman, T. T. M. C. A. (2013) · Journal of Postgenomics Drug & Biomarker Development · doi:10.4172/2153-0769.1000117 · Cited by 5
First Do No Harm?: What Role Should Considerations of Potential Harm Play in Revising the DSM?
Cooper, R. (2016) · Philosophy, psychiatry & psychology · doi:10.1353/ppp.2016.0010 · Cited by 5
F(r)ische fürs Gehirn
Leutgeb, V., Köchel, A., Lang, L., Koch, J., & Schienle, A. (2015) · Kindheit und Entwicklung · doi:10.1026/0942-5403/a000164 · Cited by 5
Psychosis Risk Syndrome: What Now?
Sentissi, O., ANDREOU, M. A., Moeglin, C., Curtis, L., & BROSCH, M. S. (2017) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000272 · Cited by 5
Should the diagnostic boundaries of schizophrenia be expanded?
David, A. S. (2011) · Cognitive Neuropsychiatry · doi:10.1080/13546805.2011.554276 · Cited by 5
Omega-3 fatty acids in mental disorders: from neurobiological and metabolic mechanisms to therapeutic potential
Fleig, K., Haslinger, L., Dawczynski, C., & Kolassa, I. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1748196 · Cited by 5
Remediation and Cognitive Enhancers in Schizotypal Personality Disorder
Graff, F. S., McClure, M. M., & Siever, L. J. (2014) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-014-0027-0 · Cited by 4
N-Acetylcysteine and a Specialized Preventive Intervention for Individuals at High Risk for Psychosis: A Randomized Double-Blind Multicenter Trial
Wasserthal, S., Muthesius, A., Hurlemann, R., Ruhrmann, S., Schmidt, S. J., Hellmich, M., Schultze‐Lutter, F., Klosterkötter, J., Müller, H., Meyer‐Lindenberg, A., et al. (2024) · Schizophrenia Bulletin Open · doi:10.1093/schizbullopen/sgae005 · Cited by 4
Cognitive impairments in first-episode psychosis patients with attenuated niacin response
Ju, M., Long, B., Wei, Y., Tang, X., Xu, L., Gan, R., Cui, H., Tang, Y., Yi, Z., Liu, H., et al. (2025) · Schizophrenia Research Cognition · doi:10.1016/j.scog.2025.100346 · Cited by 4
Relationships Between Immune‐Inflammatory Features and Social Cognitive Impairments in Patients With Schizophrenia Spectrum Disorders: A Systematic Review
Carpentier, A., Zampetas, D., Durand, A., Naassïla, M., & Bralet, M. (2025) · Brain and Behavior · doi:10.1002/brb3.70384 · Cited by 4
Early interventions for people with psychotic disorders
Power, P., & McGorry, P. D. (2011) · doi:10.1093/med/9780199565498.003.0072 · Cited by 4
Self-citation
Interventions Targeting Social and Vocational Dysfunction in Individuals with a Schizophrenia Spectrum Disorder
Bartholomeusz, C. F., Killackey, E. J., Thompson, A. D., & Wood, S. J. (2011) · Springer eBooks · doi:10.1007/978-94-007-0834-1_9 · Cited by 4
Changes in triglyceride levels in ultra‐high risk for psychosis individuals treated with omega‐3 fatty acids
Mossaheb, N., Papageorgiou, K. G., Schäfer, M. R., Becker, J., Schloegelhofer, M., & Amminger, G. P. (2015) · Early Intervention in Psychiatry · doi:10.1111/eip.12275 · Cited by 4
Self-citation
Immunomodulation as Therapeutic Approach in Schizophrenia and Depression: State of the Art
Müller, N. (2015) · Current topics in neurotoxicity · doi:10.1007/978-3-319-13602-8_17 · Cited by 4
The Question of Pro-Inflammatory Immune Activity in Schizophrenia and the Potential Importance of Anti-Inflammatory Drugs
Arolt, V., & Ambrée, O. (2013) · Modern trends in psychiatry · doi:10.1159/000343972 · Cited by 4
ApoE elevation is associated with the persistence of psychotic experiences from age 12 to age 18: Evidence from the ALSPAC birth cohort
Sabherwal, S., Föcking, M., English, J. A., Fitzsimons, S., Hryniewiecka, M., Wynne, K. J., Scaife, C., Healy, C., Cannon, M. D., Belton, O., et al. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.05.002 · Cited by 5
Health Care Resource Utilization and Cost Before Initial Schizophrenia Diagnosis
Wallace, A. E., Barron, J. O., York, W., Isenberg, K. E., Franchino‐Elder, J., Sidovar, M. F., & Sand, M. S. (2019) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2019.25.10.1102 · Cited by 4
Urinary biopyrrins and free immunoglobin light chains are biomarker candidates for screening at‐risk mental state in adolescents
Wake, R., Araki, T., Fukushima, M., Matsuda, H., Inagaki, T., Hayashida, M., Hashioka, S., Horiguchi, J., Inagaki, M., Miyaoka, T., et al. (2021) · Early Intervention in Psychiatry · doi:10.1111/eip.13154 · Cited by 4
Antioxidant Interventions in Neuropsychiatric Disorders
Pillai, A., & Yao, J. K. (2014) · Oxidative stress in applied basic research and clinical practice · doi:10.1007/978-1-4939-0440-2_25 · Cited by 4
Maternal Nutritional Deficiencies and Schizophrenia
Eyles, D. W., & Dean, A. J. (2015) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-12-800981-9.00015-8 · Cited by 4
Complementary and Integrative Health Practices for Depression
Haefner, J. (2017) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20170905-02 · Cited by 4
Prise en charge des comorbidités cardio-vasculaires chez les jeunes patients souffrant d’une psychose débutante : état des lieux et perspectives thérapeutiques
Frajerman, A., Morin, V., Chaumette, B., Kébir, O., & Krebs, M. (2020) · L Encéphale · doi:10.1016/j.encep.2020.03.007 · Cited by 5
Diagnostic uncertainty, antipsychotic dosing, and optimal psychosocial interventions: Unanswered questions in first-episode psychosis
Pierre, J. M. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.11.042 · Cited by 4
Clinical Evaluation and Intervention of Emerging Psychosis: A Mentalization-Informed Perspective
Debbané, M., Salaminios, G., Weijers, J. G., Fonagy, P., Fonseca‐Pedrero, E., & Armando, M. (2022) · Springer eBooks · doi:10.1007/978-3-031-09058-5_7 · Cited by 4
Therapeutic Considerations in Individuals at Clinical Risk for Developing Psychosis
Singh, F., DeJoseph, M. L., & Cadenhead, K. S. (2014) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-014-0009-2 · Cited by 4
How should we intervene in psychosis risk syndromes?
Wang, J., Jiang, K., Zhang, T., Li, H., Woodberry, K. A., & Seidman, L. J. (2013) · PubMed Central · doi:10.3969/j.issn.1002-0829.2013.01.003 · Cited by 4
Neurodevelopmental and Neuropsychiatric Disorders
Monji, A., Maezawa, I., Mizoguchi, Y., Kato, T. A., & Jin, L. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1429-6_14 · Cited by 4
Happiness and Mental Health
Anwar‐McHenry, J., Donovan, R., & Egger, G. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-810401-9.00016-4 · Cited by 4
Food Additives and Behavior: First Genetic Insights
Kaplan, B. J. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.10060795 · Cited by 4
Evidence that treatment prevents transition to psychosis in ultra-high-risk patients remains questionable
Amos, A. J. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.01.003 · Cited by 4
Immunoinflammatory Therapies in Psychiatry: Current Evidence Base
Menon, V., & Ameen, S. (2017) · Indian Journal of Psychological Medicine · doi:10.4103/ijpsym.ijpsym_505_17 · Cited by 4
Shared genetic basis informs the roles of polyunsaturated fatty acids in brain disordersPreprint
Xu, H., Sun, Y., Francis, M., Cheng, C. F., Modulla, N. T. R., Brenna, J. T., Chiang, C. W. K., & Ye, K. (2023) · medRxiv · doi:10.1101/2023.10.03.23296500 · Cited by 4
Effect of n-3 polyunsaturated fatty acids on the treatment of schizophrenia: an updated systematic review and meta-analysis
Lin, C., Lee, J., Peng, T., Tsai, P.-Y., Huang, P.-H., Lee, M., & Chen, S. M. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-07508-6 · Cited by 3
Schizophrenia and psychosis in children and adolescents: An inspiring journey of scientific progress and the rich influences of history and religion
Greydanus, D. E., Azeem, M. W., & Nazeer, A. (2025) · Disease-a-Month · doi:10.1016/j.disamonth.2025.101983 · Cited by 3
DSM-5: ¿SÍNDROME DE PSICOSIS ATENUADA?
Fonseca‐Pedrero, E., Paíno, M., & Fraguas, D. (2013) · Consultation of the Doctoral Thesis Database (TESEO) (Ministerio de Educación, Cultura y Deporte) · Cited by 2
Early Intervention in Emerging Psychosis: State of the Art and Future Perspectives
McGorry, P. D., & Goldstone, S. D. (2016) · Key issues in mental health (Online)/Key issues in mental health (Print) · doi:10.1159/000440911 · Cited by 3
Self-citation
Getting in Early: Early Intervention Services for Psychosis
Gates, J., & Killackey, E. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815012-2.00024-9 · Cited by 3
Neurobiological Principles: Psycho-Neuro-Immuno-Endocrinology
Müller, N. (2020) · Springer eBooks · doi:10.1007/978-3-319-56015-1_2-1 · Cited by 3
Causal Relationships between Polyunsaturated Fatty Acids and Colon Polyps: A Two-Sample Mendelian Randomization Study
Shen, N., Ba, Q., & Lu, Y. (2024) · Nutrients · doi:10.3390/nu16132033 · Cited by 3
Impact of second-generation antipsychotics monotherapy or combined therapy in cytokine, lymphocyte subtype, and thyroid antibodies for schizophrenia: a retrospective study
Guo, X., Kong, L., Wen, Y., Chen, L., & Hu, S. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-06141-z · Cited by 3
Polyunsaturated Fatty Acids in Adult Psychiatric Disorders: A Comprehensive Overview
Saah, T. C., Garlow, S. J., & Rapaport, M. H. (2015) · Current topics in neurotoxicity · doi:10.1007/978-3-319-13602-8_18 · Cited by 3
Quantitative System Pharmacology (QSP): An Integrative Framework for paradigm change in the treatment of the first-episode schizophrenia
Gaillard-Bigot, F., Zendjidjian, X., Kheloufi, F., Cassé‐Perrot, C., Guilhaumou, R., Micallef, J., Fakra, É., Azorin, J., & Blin, O. J. (2018) · L Encéphale · doi:10.1016/s0013-7006(19)30077-6 · Cited by 3
Understanding the link between maternal infections and neurodevelopmental disorders in offspring: The role of abnormalities in metabolism of polyunsaturated fatty acids
Hashimoto, K. (2019) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2019.07.010 · Cited by 3
Alteration in plasma docosahexaenoic acid levels following oral administration of ethyl icosapentate to rats
Onozato, M., Okanishi, Y., Akutsu, M., Okumura, I., Nemoto, A., Takano, K., Sakamoto, T., Ichiba, H., & Fukushima, T. (2019) · Practical Laboratory Medicine · doi:10.1016/j.plabm.2019.e00143 · Cited by 3
Acute Management of Schizophrenia
Janicak, P. G. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0656-7_7 · Cited by 3
The Impact of Oxidative Stress on Dopaminergic Neurotransmission
Deslauriers, J., Sarret, P., & Grignon, S. (2014) · Oxidative stress in applied basic research and clinical practice · doi:10.1007/978-1-4939-0440-2_10 · Cited by 3
The 4th Schizophrenia International Research Society Conference, 5–9 April 2014, Florence, Italy: A summary of topics and trends
Abayomi, O., Amato, D., Bailey, C. C., Bitanihirwe, B. K. Y., Bowen, L., Burshtein, S., Cullen, A. E., Fusté, M., Herrmann, A. P., Khodaie, B., et al. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.08.032 · Cited by 4
Essential Fatty Acids for Childhood Mental Health Disorders
Gracious, B., Gupta, L., & Arnold, L. E. (2015) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-015-0037-6 · Cited by 3
Intervening in clinical research to prevent the onset of psychoses: conflicts and obligations
Lysaght, T., Capps, B., Campbell, A. V., Subramaniam, M., & Chong, S. (2011) · Journal of Medical Ethics · doi:10.1136/medethics-2011-100008 · Cited by 3
Purification and function analysis of the Δ-17 fatty acid desaturase with or without transmembrane domain
Zhou, H., & Wang, C. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4790 · Cited by 3
ACTUALIZACIÓN EN LA PREVENCIÓN DE LOS TRASTORNOS DEL ESPECTRO PSICÓTICO
Fonseca‐Pedrero, E., Inchausti, F., & Rioja, U. D. L. (2018) · Papeles del Psicólogo - Psychologist Papers · doi:10.23923/pap.psicol2018.2860 · Cited by 4
Proteomics for diagnostic and therapeutic blood biomarker discovery in schizophrenia and other psychotic disorders
Cotter, D., Sabherwal, S., & Schubert, K. O. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813176-3.00025-0 · Cited by 3
Omega-3 Polyunsaturated Fatty Acids and Antioxidants for the Treatment of Schizophrenia: A Role for Magnetic Resonance Imaging
Clari, R., McNamara, R. K., & Szeszko, P. R. (2020) · Springer eBooks · doi:10.1007/978-3-030-35206-6_19 · Cited by 3
Antipsychotic natural products
Skalicka‐Woźniak, K., & Gertsch, J. (2020) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2020.03.004 · Cited by 3
Nutritional proceedings in schizophrenia
Groszewska, K., Suchecka, D., Preś, J., Samochowiec, J., & Kucharska–Mazur, J. (2015) · Postępy Psychiatrii i Neurologii · doi:10.1016/j.pin.2015.07.001 · Cited by 3
Health Care Resource Utilization and Cost Before Initial Schizophrenia Diagnosis
Wallace, A. E., Barron, J. O., York, W., Isenberg, K. E., Franchino‐Elder, J., Sidovar, M. F., & Sand, M. S. (2019) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2019.19009 · Cited by 3
Integrative and Complementary Medicine in Psychiatry
Sarris, J. J., Gerbarg, P. L., Brown, R. P., & Muskin, P. R. (2015) · Wiley eBooks · doi:10.1002/9781118753378.ch110 · Cited by 3
Neuroimaging the Infant: The Application of Modern Neurobiological Methods to the Neurodevelopmental Hypothesis of Schizophrenia
Ross, R. G. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.10060860 · Cited by 3
Omega-3 supplements in the prevention and treatment of youth depression and anxiety: A scoping reviewPreprint
Reily, N. M., Tang, S., Negrone, A., Gan, D. Z. Q., Sheanoda, V., & Christensen, H. M. (2022) · medRxiv · doi:10.1101/2022.06.26.22276840 · Cited by 3
Effects of Fish-Oil Consumption on Psychological Function Outcomes in Psychosis: A Systematic Review and Dose–Response Meta-Analysis of Randomized Controlled Trials
Montazer, M., Ebrahimpour‐Koujan, S., Surkan, P. J., & Azadbakht, L. (2022) · Advances in Nutrition · doi:10.1093/advances/nmac083 · Cited by 2
Nutrient deficiencies in patients with psychiatric disorders – investigating how low levels of omega-3s, B vitamins and magnesium affect mental health conditions like depression, schizophrenia and bipolar disorder
Paul, L. T. D., Das, P. K., Aushe, K. J., Rahaman, A. T., & Nizamuddin, H. M. (2025) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20253135 · Cited by 2
Nutritional Management of Schizophrenia: Gut-Brain Axis Mechanisms and Dietary Interventions
Vakili, O., Motamed, M., Taghizadeh, M., & Khatami, S. H. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-05751-w · Cited by 2
Clinical High-Risk for Psychosis in Adolescents: Updated Meta-analysis on Transition Rates and Antipsychotic Prognostic Value
Raballo, A., Poletti, M., Lavalle, R., & Preti, A. (2026) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2026.03.014 · Cited by 2
Controversies in Psychiatry and DSM-5: The Relevance for Social Work
Littrell, J. L., & Lacasse, J. R. (2012) · Cited by 2
Intervention Strategies for Attenuated Psychosis Syndromes: A Review of Current Practice, Evidence, and Future Directions
Shapiro, D. I., Woodberry, K. A., Li, H., & Seidman, L. J. (2019) · Springer eBooks · doi:10.1007/978-3-030-17336-4_3 · Cited by 2
Shared Decision Making in Mental Health: International Perspectives on Implementation
Ramon, S., Zisman‐Ilani, Y., Quirk, A., & Zisman-Ilani (2022) · Frontiers research topics · doi:10.3389/978-2-88974-217-2 · Cited by 2
Essential fatty acids in farmed tambaqui (Colossoma macropomum) from the Brazilian Amazon Area
dos Santos, T. S., Souza, E. D. S., Bragagnolo, N., da Costa, A. R., Filho, J. J., & de Almeida, N. M. (2022) · Acta Scientiarum Animal Sciences · doi:10.4025/actascianimsci.v44i1.57090 · Cited by 2
NUTRIÇÃO E SAÚDE MENTAL: A NECESSIDADE DE UMA ABORDAGEM MULTIDISCIPLINAR PARA O CUIDADO INTEGRAL DO PACIENTE
Melo, V. D. S., Bandeira, M. D. S., Torres, M. T. P., dos Santos, N. T. Q., Baptista, K. R. D. C., da Silva, E. A., Marques, M. R. D. C., Barboza, K. R. M., Gomes, C. M. D. C. P., & Tecchio, J. V. S. (2023) · Editora Científica Digital eBooks · doi:10.37885/230914410 · Cited by 2
Advancing Neuroprotective-Based Treatments for Schizophrenia
Ritsner, M. S., & Lerner, V. (2011) · Springer eBooks · doi:10.1007/978-94-007-0834-1_3 · Cited by 2
Research Policies for Schizophrenia in the Global Health Context
Dyke, C. V. (2013) · International Journal of Mental Health · doi:10.2753/imh0020-7411420104 · Cited by 2
Do we face the same dilemma on pediatric psychopharmacology in low and middle income countries?
Rohde, L. A. (2013) · World Psychiatry · doi:10.1002/wps.20035 · Cited by 2

Authors: Amminger, G. P., Schäfer, M. R., Papageorgiou, K., Klier, C. M., Cotton, S. M., Harrigan, S. M., Mackinnon, A., McGorry, P. D., & Berger, G. E.
Affiliations: Medical University of Vienna (AT)
The University of Melbourne (AU)
Clienia AG (CH)
ORCID: Amminger, G. Paul
Papageorgiou, Konstantinos
Klier, Claudia M.
Cotton, Sue M.
Mackinnon, Andrew
McGorry, Patrick D.
Berger, Gregor E.
Venue: Archives of General Psychiatry
Publisher: American Medical Association (AMA)
Published: 2010-02-01
Volume: 67
Issue: 2
Pages: 146
ISSN: 0003-990X (ISSN-L)
DOI: 10.1001/archgenpsychiatry.2009.192
OpenAlex: W2130372506
Cited by: 896
References: 45
Citations by year: 2026: 13 · 2025: 20 · 2024: 29 · 2023: 22 · 2022: 20 · 2021: 51 · 2020: 42 · 2019: 59 · 2018: 33 · 2017: 52 · 2016: 69 · 2015: 82 · 2014: 95 · 2013: 85 · 2012: 98
FWCI: 92.57
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Archives of General Psychiatry (publishedVersion)
PubMed (publishedVersion)
Funders: Stanley Medical Research Institute (03T-315)
Topics: Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
Keywords: omega-3 polyunsaturated fatty acids, clinical high risk for psychosis, schizophrenia, adolescents and young adults, n-6/n-3 ratio, erythrocyte fatty acids, positive symptoms, negative symptoms, functional outcome, dietary supplementation, psychosis prevention, omega-3 deficiency
MeSH terms: Adolescent, Adult, Dose-Response Relationship, Drug, Double-Blind Method, Female, Health Status, Humans, Male, Patient Acceptance of Health Care, Psychotic Disorders, Risk Factors, Schizotypal Personality Disorder, Severity of Illness Index, Fatty Acids, Omega-3, Treatment Outcome, Diagnostic and Statistical Manual of Mental Disorders, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Long-Chain ω-3 Fatty Acids for Indicated Prevention of Psychotic Disorders: A Randomized, Placebo-Controlled Trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks